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INTRODUCTION
Heart failure (HF) is a huge challenge for cardiology of the 
twenty-first century. The commonly recognised treatments 
showing beneficial effects on prognosis, quality of life, and 
safety apply to patients with heart failure with reduced left 
ventricular ejection fraction (HFrEF). The treatment of this 
form of HF is based on the use of beta-blockers (BB) and 
angiotensin-converting enzyme inhibitors (ACEI) or, if ACEIs 
are not tolerated, angiotensin-2 receptor blocker (ARB) and, 
in symptomatic patients with left ventricular ejection fraction 
(LVEF) ≤ 35%, mineralocorticoid receptor antagonists (MRA). 
In 2015, a new medicinal product was registered in Europe, 
a combination of valsartan (ARB) and sacubitril (a prodrug 
that converts into an active neprilysin inhibitor). By now 
this combination drug is a first-in-class angiotensin receptor 
neprilysin inhibitor (ARNI). The most recent guidelines of the 
European Society of Cardiology (ESC) on treatment of HF as-
signed it a high class of recommendation (IB) [1] and make it 
another milestone in the medical therapy of chronic HFrEF. It 
is recommended as a replacement for ACEI or ARB in selected 
patients; however, some discrepancies between the European 
and American guideline documents make clinicians uncertain 
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in whom and how to start treatment with sacubitril/valsartan 
in clinical practice.
This position paper provides information on new oppor-
tunities for medical therapy of HFrEF using sacubitril/valsartan 
in daily practice. It presents the position of Polish experts who 
deal with HF on this ground-breaking therapy and gives practi-
cal guidance on implementation, monitoring of effects, and 
safety of treatment with sacubitril/valsartan composition [2–4].
SACUBITRIL/VALSARTAN IN GUIDELINES  
OF VARIOUS MEDICAL ASSOCIATIONS
Sacubitril/valsartan (Entresto™) was first mentioned in the posi-
tion statement on the implementation of guidelines to clinical 
practice by the Canadian Cardiovascular Society Heart Failure 
Companion in 2014 [5]. This information appeared before the 
drug was registered in Canada, therefore the term “conditional 
recommendation” was used. The strong position of the drug 
results from the high-quality data from the PARADIGM-HF 
study [2]. Sacubitril/valsartan is recommended to replace ACEI 
or ARB in all patients who, in spite of triple therapy (ACEI or 
ARB, BB and MRA), remain symptomatic at New York Heart 
Association (NYHA) functional class II–IV, have LVEF < 40%, 
increased natriuretic peptide level or HF hospitalisation in 
the last 12 months, serum potassium level < 5.2 mmol/L, 
and estimated glomerular filtration rate (eGFR) ≥ 30 mL/min. 
The authors highlight the need to monitor of potassium and 
creatinine levels during therapy.
Other societies that mention sacubitril/valsartan in the 
HF guidelines include the ESC [1] and ACC/AHA/ HFSA [6]. 
The ECS algorithm of pharmacological treatment of chronic 
HFrEF recommends the use of sacubitril/valsartan in place of 
ACEI (or ARB) in ambulatory patients with LVEF ≤ 35%, who 
are still symptomatic at NYHA class II–IV, despite treatment 
with ACEI (or ARB), BB, and MRA (class I, level of evidence B) 
in order to further reduce the risk of HF hospitalisation and 
death (Table 1).
Depending on indications, sacubitril/valsartan can be 
combined with ivabradine, electrotherapy (implantable 
cardioverter-defibrillator, cardiac resynchronisation therapy 
[CRT]), and diuretics.
In the description of sacubitril/valsartan treatment strat-
egy the ESC guidelines’ authors refer to the PARADIGM-HF 
study. In accordance with the study inclusion criteria, they 
recommend using this drug in symptomatic HF subjects at 
NYHA class II–IV, with decreased LVEF (≤ 35%), elevated 
serum natriuretic peptide level (B-type natriuretic peptide 
[BNP] ≥ 150 pg/mL or N-terminal pro B-type natriuretic 
peptide [NT-proBNP] ≥ 600 pg/mL, and BNP ≥ 100 pg/mL 
or NT-proBNP ≥ 400 pg/mL for subjects hospitalised for HF 
in the past 12 months), and eGFR ≥ 30 mL/min/1.73 m2. The 
candidates should well tolerate ACEI doses equivalent to 
10 mg enalapril daily. The target dose of sacubitril/valsartan 
is 97/103 mg twice daily (97 mg of sacubitril and 103 mg of 
valsartan). The 2016 ESC guidelines also support the strong 
position of sacubitril/valsartan therapy in the treatment of 
ventricular arrhythmias (Table 1) [1].
The American guidelines (ACC/AHA/HFSA) were pub-
lished simultaneously with the European ones and present 
an update on HF therapy [6]. Sacubitril/valsartan composi-
tion is recommended as an alternative to ACEI or ARB in 
combination with BB and MRA in patients with HFrEF and 
LVEF ≤ 40%, NYHA class II and III, who are on a stable dose 
of ACEI/ARB, in order to reduce morbidity and mortality 
(Table 1). They also point out safety aspects associated with 
this treatment, namely the risk of hypotension and (rarely) 
angioedema. It was also highlighted that, in order to facilitate 
the initiation of treatment and its optimisation, three dosages 
of the approved ARNI formulation are marketed, including 
Table 1. Summary of guidelines for the use of sacubitril/valsartan in HFrEF. Based on the reference [1, 6]
Class Level Recommendation
ACC/AHA/HFSA 2016
I B-R In patients with chronic symptomatic HFrEF NYHA class II or III, who tolerate an ACEI or ARB,  
replacement by an ARNI is recommended to further reduce morbidity and mortality
III B-R ARNI should not be administered concomitantly with ACEI or within 36 h of the last dose of an ACEI
III C-EO ARNI should not be administered to patients with a history of angioedema
ESC 2016
I B Sacubitril/valsartan is recommended as a replacement for an ACEI to further reduce the risk of HF 
hospitalisation and death in ambulatory patients with HFrEF, who remain symptomatic despite  
optimal treatment with an ACEI, a beta-blocker, and an MRA
I A Treatment with beta-blocker, MRA, and sacubitril/valsartan reduces the risk of sudden death and  
is recommended for patients with HFrEF and ventricular arrhythmias (as for other patients)
ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin-2 receptor blocker; ARNI — angiotensin receptor neprilysin inhibitor;  
HF — heart failure; HFrEF — heart failure with reduced left ventricular ejection fraction; MRA — mineralocorticoid receptor antagonists;  
NYHA — New York Heart Association
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one untested in the clinical study in which the target daily 
dose was 2 × 97/103 mg. They also mention that the clinical 
experience should provide further information on the toler-
ability and optimal dose titration strategy.
MECHANISMS OF ACTION  
OF SACUBITRIL/VALSARTAN
The new drug is a preparation containing two molecules in 
the form of sodium salt complex of valsartan and sacubitril 
acting on two main signalling pathways being activated in HF. 
It belongs to a new class of drugs — ARNIs —  and is so far 
the only representative.
The first active molecule is well-known valsartan — angio - 
tensin 2 (AT2) receptor blocker. AT2 plays a key role in car-
diovascular diseases, i.e. hypertension, HF, and diabetes. The 
impact of AT2 mainly depends on the activation of AT1 re-
ceptors (G protein-coupled) located in blood vessels, cardiac 
muscle, kidneys, and adrenal glands. Their overstimulation 
typical for HF by AT2 excess leads to unfavourable remodel-
ling of blood vessels (vasoconstriction, wall remodelling) and 
myocardium (worsening of hypertrophy and fibrosis), as well 
as deleterious effects on renal and cerebral microcirculation, 
impaired insulin sensitivity, increased sympathetic activity, and 
initiation of thrombotic and inflammatory reactions. In view 
of these negative actions of AT2 excess, blocking AT2 effector 
by valsartan, namely the AT receptor, leads to a reversal of 
many of the above-mentioned cardiovascular adverse effects.
The second active agent is sacubitril. It inhibits neutral 
endopeptidase (NEP) decomposing sulphide bonds and 
thereby destroying the ring structure of natriuretic peptide 
(NP) molecules. This enzyme is located in the endothelial 
cells, vascular smooth muscles, neutrophils, epithelial cells of 
renal tubules, as well as myocardial tissue. HF is associated 
with an increase of NEP expression and activity resulting in 
an increased deactivation of NP, thus reducing their beneficial 
effects. The positive effect of NP depends on the activation 
of specific receptors (NPR-A/NPR-B). Their activation results 
in the inhibition of adverse remodelling of myocardial and 
vascular cells and also antagonises the excessive activation of 
the renin–angiotensin–aldosterone system. Hence, the use of 
NEP inhibitor, sacubitril, increases the bioavailability of NP 
and its favourable cellular effects.
Considering the mechanisms of action of sacubi-
tril/valsartan, it should also be taken into account that NEP is 
a non-specific endopeptidase that decays many other sub-
stances activated in HF, such as bradykinin, adrenomedullin, 
angiotensin, and endothelin. Consequently, the use of ARNI 
leads to a multi-cell effect, which translates to a favourable 
overall effect observed in the clinical trials.
PARADIGM-HF STUDY
There is little experience with the new class of drugs, ARNI, 
and, substantially, their first representative, i.e. combination 
of valsartan and sacubitril, so far. The PARADIGM-HF study 
(Prospective comparison of ARNI with ACEI to Determine the 
Impact on Global Mortality and Morbidity in Heart Failure) 
was the first study in which the impact of the drug (called 
LCZ696) on morbidity and mortality was measured in patients 
with HFrEF.
PARADIGM-HF methodology
PARADIGM-HF was an international, randomised, dou-
ble-blind study involving 8442 patients, which compared the 
efficacy and safety of two treatment strategies — enalapril 
vs. a combination of sacubitril and valsartan (LCZ696) [7]. 
Enalapril was chosen as the reference drug for LCZ696 as 
it was the only ACEI that was proved to reduce mortality in 
a wide spectrum of patients with HFrEF. Based on the SOLVD-T 
and CONSENSUS studies, enalapril 10 mg per day was ap-
proved by the regulatory authorities as the “gold standard” 
among ACEIs [8].
Patients meeting the following criteria were enrolled [7]:
 — age over 18 years;
 — LVEF ≤ 35% (originally LVEF ≤ 40%);
 — clinical signs and symptoms of HF NYHA class II–IV;
 — BNP ≥ 150 pg/mL or NT-proBNP ≥ 600 pg/mL, and 
for patients hospitalised for HF in the past 12 months 
prior to enrolment: BNP ≥ 100 pg/mL or NT-proBNP 
≥ 400 pg/mL;
 — ACEI or ARB in daily doses equivalent to 10 mg of enal-
april for at least one month prior to enrolment;
 — BB in stable dose for at least one month prior to enrol-
ment, unless contraindicated or intolerable;
 — considering the use of MRAs with regard to renal function, 
serum potassium, and tolerability, and the drug dose also 
had to be stable for at least four weeks prior to enrolment. 
The following exclusion criteria were applied:
 — history of intolerance to ACEI or ARB or intolerance of 
these drugs in doses equivalent to 10 mg of enalapril daily;
 — history of angioedema;
 — decompensated HF requiring the use of intravenous 
drugs;
 — symptomatic hypotension or systolic blood pressure (SBP) 
< 100 mm Hg at the first visit (screening), or less than 
95 mm Hg during subsequent visits;
 — hyperkalaemia (serum K+ > 5.2 mmol/L) and/or eGFR 
< 35 mL/min/1.73 m2 at the first visit or K+> 5.4 mmol/L 
and/or eGFR reduction by > 35% during subsequent 
visits;
 — acute coronary syndrome, cerebrovascular event or vas-
cular intervention, CRT implantation within three months 
prior to randomisation, or planned CRT implantation.
Prior to randomisation, all patients underwent sequen-
tial, single-blind treatment (run-in phase) with enalapril and 
LCZ696 to confirm good tolerability of the target doses. From 
the initially screened 10,521 patients, after completion of the 
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run-in phase, ultimately 8442 subjects were randomised to 
the study treatment. The study compared the safety and ef-
ficacy of sacubitril/valsartan 200 mg twice daily and enalapril 
10 mg twice daily [7].
The primary, composite endpoint was cardiovascular 
death or HF hospitalisation. The secondary endpoints assessed 
weather sacubitril/valsartan is superior to enalapril using:
 — clinical improvement (reduction of severity of HF 
symptoms assessed by the Kansas City Cardiomyopathy 
Questionnaire [KCCQ]);
 — delay to all-cause mortality (mortality rate);
 — delay to new onset atrial fibrillation and/or deterioration 
of renal function.
The median follow-up period was 27 months, and the 
patients were treated for up to 4.3 years.
General patient characteristics
The study group was a typical population with advanced HF. 
The majority of patients (78%) in the PARADIGM-HF study 
were males at an average age of 64 years [7, 9]. As many 
as 93% of patients used BB, and 56% were taking MRA [9]. 
In nearly 60% of subjects HFrHF was caused by ischaemic 
heart disease, and 43% had previous myocardial infarction. 
Hypertension was present in 71%, diabetes in 34%, and atrial 
fibrillation in 37% of patients. Despite potentially optimal 
pharmacotherapy, the quality of life of patients enrolled in the 
PARADIGM-HF study was reduced, primarily due to the ongo-
ing clinical symptoms of HF. The vast majority of patients had 
a functional capacity of NYHA class II (70%). The average LVEF 
was 29% and mean NT-proBNP level was 1608 pg/mL [9].
PARADIGM-HF results
The study was terminated earlier (median follow-up period 
— 27 months) because of clear benefits of sacubitril/valsar-
tan compared to enalapril (Table 2). The primary endpoint 
occurred in 21.8% of subjects in the ARNI group and in 
26.5% of the ACEI group, the relative risk reduction was 
20% (p < 0.001). In the sacubitril/valsartan group the overall 
mortality was lower (17.0%) as compared to the enalapril 
group (19.8%). The majority of deaths (80.9%) in the overall 
population was of cardiovascular aetiology. Among patients 
who died, cardiovascular death was observed in 13.3% and 
16.5% of subjects in ARNI and ACEI group, respectively 
(p < 0.001). The use of sacubitril/valsartan was more ef-
fective than enalapril in prevention of both sudden cardiac 
death (hazard ratio [HR] 0.80; 95% confidence interval [CI] 
0.68–0.94, p = 0.008) and mortality associated with progres-
sion of HF (HR 0.79; 95% CI 0.64–0.98; p = 0.034) [10].
The use of ARNI was also associated with a 21% reduc-
tion in the risk of hospitalisation for HF and clinical improve-
ment (reduction in worsening of symptoms). There were no 
significant differences in the incidence of new onset atrial 
fibrillation or end-stage renal failure [2].
The safety analysis showed a higher incidence of hypoten-
sion in the ARNI group, while more cases of hyperkalaemia and 
increased serum creatinine were attributable to enalapril [2]. 
Eventually the treatment was interrupted due to adverse 
events in fewer patients receiving sacubitril/valsartan than 
in those taking enalapril (10.7% vs. 12.3%, respectively; 
p = 0.03), including impaired renal function (0.7% and 1.4%, 
respectively; p = 0.002) [2]. Benign angioedema was observed 
more frequently in patients treated with LCZ696 than enalapril 
(19 vs. 10 subjects; p = NS).
The additional analysis of study results showed that an 
independent risk factor for the primary end point was low 
LVEF. ARNI effectively reduced the risk of primary outcome 
in each of the analysed ranges of LVEF [11].
The new drug reduced the risk of hospitalisation for 
worsening HF (by 23% compared to the enalapril group, 
p < 0.001), the risk of hospitalisation at the intensive care 
Table 2. Summary of main results of the PARADIGM-HF study [2]
Outcomes Hazard ratio  
(95% CI)
Improvement of risk /result  
in advantage of LCZ696
p
Primary outcome
Death from cardiovascular causes or first hospitalisation  
for worsening heart failure
0.80 (0.73–0.87) 20% < 0.001
Death from cardiovascular causes 0.80 (0.71–0.89) 20% < 0.001
First hospitalisation for worsening heart failure 0.79 (0.71–0.89) 21% < 0.001
Secondary outcomes
Death from any cause 0.84 (0.76–0.93) 16% < 0.001
Change in KCCQ clinical summary score at 8 months 1.64 (0.63–2.65) 64% 0.001
New-onset atrial fibrillation 0.97 (0.72–1.31) NS
Decline in renal function 0.86 (0.65–1.13) NS
CI — confidence interval; KCCQ — Kansas City Cardiomyopathy Questionnaire
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unit, and the need for intravenous positive inotropes (by 18%, 
p = 0.005, and 31%, p < 0.001, respectively). The benefits 
of LCZ696 were the same in all pre-specified subpopulations 
of the PARADIGM-HF study [11–13].
It is worth noting that the ARNI group was observed to 
show rapid and sustained reduction in biomarkers of myocar-
dial damage: both troponin and NT-proBNP [14].
The results of one of the post hoc analyses of the PAR-
ADIGM-HF study suggest that the use of sacubitril/valsartan, 
also in doses lower than the target dose, was more effective in 
the reduction of risk of cardiovascular death or hospitalisation 
for HF in comparison with the corresponding lower doses of 
enalapril [15].
Benefits of sacubitril/valsartan treatment
According to the outcomes of the PARADIGM-HF study, after 
a median follow-up of 27 months, the incidence of primary 
outcome was reduced by 20% in the sacubitril/valsartan 
group. The number needed to treat (NNT), i.e. the number 
of patients who had to undergo an intervention for a speci-
fied period of time to prevent one adverse endpoint, was 21. 
It means that in order to prevent the occurrence of one 
cardiovascular death or hospitalisation for HF 21 patients 
with symptomatic HF need to be treated for 27 months and 
their clinical and demographic characteristic must be similar 
to the PARADIGM-HF population. In addition, the analysis 
of the PARADIGM-HF results also showed that to prevent 
one death in the HF population a 12-month therapy with 
sacubitril/valsartan should involve 80.3 patients.
TITRATION STUDY
The PARADIGM-HF study population consisted of patients 
who had already been treated with optimal doses of enalapril, 
and it is well known that in clinical practice many patients 
are not treated with the target doses of ACEI/ARB. Therefore, 
it was decided to assess the tolerance to various regimens 
of initiation and titration of sacubitril/valsartan in a wider 
population than previously studied, being representative for 
the real-life HFrEF population. Thus, the TITRATION study in-
cluded both inpatients and outpatients, also taking small doses 
of ACEI/ARB or not using these drugs earlier at all. Increased 
levels of natriuretic peptides on enrolment were not required.
The TITRATION study [16] compared two regimens 
of sacubitril/valsartan treatment: a conservative regimen 
for which the patient started on 50 mg twice daily for two 
weeks, followed by 100 mg twice daily for three weeks, fol-
lowed by 200 mg twice daily, and condensed titration with 
an initial dose of 100 mg twice daily for two weeks and the 
target dose equal to 200 mg twice daily. The randomisation 
into those regimens was preceded by a five-day open-label 
run-in phase: the study drug was administered to all subjects 
at a dose of 50 mg two times per day. The randomised treat-
ment lasted 11 weeks.
On the basis of ACEI/ARB treatment prior to enrol-
ment, the patients were assigned to a low-dose group that 
was defined as ≤ 160 mg valsartan or ≤ 10 mg enalapril per 
day or equivalent doses of other ACEIs or ARBs, including 
ACEI/ARB-naïve patients.
The results of this study lead to the conclusion that in 
both regimens a high percentage of patients had a chance to 
reach a high dose (77.8% in conservative regimen vs. 84.3% 
for condensed regimen; p = 0.078), both hospitalised and 
outpatient subjects as well as a low-dose group. The prolonged 
dosing (conservative) regimen can increase the chance of 
achieving the target dose in patients originally using low doses 
of ACEI/ARB (84.9% vs. 73.6%, conservative vs. condensed 
regimens; p = 0.03). The tolerability profile of sacubitril/val-
sartan did not differ from that typically observed in other 
studies involving approved HF therapies.
ADVERSE EFFECTS OF SACUBITRIL/VALSARTAN 
AND INTERACTIONS WITH OTHER DRUGS
The adverse reactions are associated with the mechanisms of 
action of two components of the preparation: sacubitril and 
valsartan. These include but are not limited to: symptomatic 
hypotension, compromised renal function, hyperkalaemia, 
and angioedema (Table 3). The understanding of the mecha-
nism of action and implementation of treatment in optimal 
patients limit the possibility of predictable adverse effects.
Symptomatic hypotension
Interference with the renin–angiotensin–aldosterone system 
may lead to more potent vasodilatory effect and symptomatic 
hypotension. These adverse effects were mainly observed in 
subjects ≥ 65 years of age, with kidney disease, and those 
with a relatively low SBP (< 112 mm Hg). Dose reduction, 
transient discontinuation, or adjustment of other hypotensive 
drugs is a proper and sufficient management.
In the PARADIGM-HF population, symptomatic hypo-
tension occurred in 14% of patients treated with LCZ696, 
and it was significantly higher than in patients treated with 
enalapril (9.2%; p < 0.001). Symptomatic hypotension with 
SBP < 90 mm Hg occurred almost five times less often and 
affected 2.7% of patients on LCZ696 and 1.4% of patients 
in the enalapril group (p < 0.001). Interpretation of the inci-
dence of this adverse effect must take into account the fact that 
patients with symptomatic hypotension or SBP < 100 mm Hg 
at screening (< 95 mm Hg at randomisation) were not in-
cluded in the study. Most episodes of hypotension did not 
require discontinuation of therapy.
Deterioration of renal function
Deterioration of renal function in patients taking sacubi-
tril/valsartan may result from hypotension and impaired renal 
perfusion. The risk is increased in dehydrated subjects or using 
non-steroidal anti-inflammatory drugs.
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In the population treated with LCZ696 elevated serum 
creatinine ≥ 2.5 mg/dL was observed in 3.3% of subjects 
— less than among those treated with enalapril (4.5%). It 
should be highlighted that GFR < 30 mL/min/1.73 m2 was 
the study exclusion criterion.
Hyperkalaemia
Monitoring of serum potassium levels is recommended es-
pecially in patients with risk factors for hyperkalaemia, i.e. 
renal dysfunction, diabetes, hypoaldosteronism, or taking 
MRAs. It should be noted that hyperkalaemia defined as se-
rum potassium concentration > 5.5 mmol/L was a common 
phenomenon in the PARADIGM-HF study. It was observed 
in both sacubitril/valsartan and enalapril subjects, in 16.1% 
and 17.3% of subjects, respectively. Potassium concentration 
higher than 6.0 mmol/L was recorded in 4.3% and 5.6% of 
patients, respectively — significantly more commonly in 
subjects treated with enalapril (p < 0.007).
Angioedema
Angioedema is one of the most serious but rare adverse ef-
fects. Previous experience with omapatrilat, which inhibited 
as many as three enzymes involved in the degradation of 
bradykinin (i.e. ACE, aminopeptidase P, and neprilysin), were 
bad in terms of the risk of angioedema. The action of sacubitril 
is limited to inhibition of neprilysin and has a negligible impact 
on the risk of this complication.
Allowing for a 36-h break between the last dose of ACEI 
and sacubitril/valsartan dose reduces the risk of angioedema. 
Angioedema involving the face usually resolves without treat-
ment. Angioedema involving the laryngeal oedema can be 
life-threatening.
Angioedema was observed in single patients in the 
PARADIGM-HF study — a slightly larger absolute number of 
patients treated with LCZ696 compared with enalapril. Symp-
toms not requiring treatment or requiring only antihistamine 
therapy were observed in ten (0.2%) patients treated with 
LCZ696 and five (0.1%) patients on enalapril. Ambulatory 
use of catecholamines or steroids was required in six (0.1%) 
and four (0.1%) patients, respectively; and hospitalisation in 
three (0.1%) and one (< 0.1%) patient, respectively. None 
of the patients presented significant airway obstruction. It 
should be underlined that a history of angioedema excluded 
candidates from enrolment into the study.
Interactions with other drugs
Interactions resulting in contraindication combined use:
 — concomitant use of sacubitril/valsartan and ACEI because 
inhibition of neprilysin and ACE may increase the risk of 
angioedema;
 — concomitant use of sacubitril/valsartan and direct renin 
inhibitors such as aliskiren in diabetic patients or in pa-
tients with renal impairment (GFR < 60 mL/min/1.73 m2) 
is contraindicated.
Interactions requiring precautions
Co-administration of drugs potentially increasing serum 
potassium and creatinine levels requires caution and moni-
toring of these biomarkers. They include potassium-sparing 
diuretics (triamterene, amiloride), mineralocorticoid recep-
tor antagonists (spironolactone, eplerenone), potassium 
supplements, and other medicines containing potassium 
(e.g. heparin).
Increased risk of worsening renal function occurs also in 
combining ARNI with non-steroidal anti-inflammatory drugs 
or selective inhibitors of cyclooxygenase-2. The high-risk 
groups include patients who are older, dehydrated, or show 
impaired kidney function at baseline.
Table 3. Adverse effects during treatment with LCZ696(2)A
Adverse effects Sacubitril/valsartan Enalapril p
Symptomatic hypotension 14.0 9.2 < 0.001
Symptomatic hypotension with SBP < 90 mm Hg 2.7 1.4 < 0.001
Increase of serum creatinine ≥ 2.5 mg/dL 3.3 4.5 0.007
Increase of serum creatinine ≥ 3.0 mg/dL 1.5 2.0 0.10
Increase of serum potassium ≥ 5.5 mmol/L 16.1 17.3 0.15
Increase of serum potassium ≥ 6.0 mmol/L 4.3 5.6 0.007
Cough 11.3 14.3 < 0.001
Angioedema:
No treatment or use of antihistamines only 0.2 0.1 0.19
Use of catecholamines or glucocorticoids without hospitalisation 0.1 0.1 0.52
Hospitalisation without airway compromise 0.1 < 0.1 0.31
Airway compromise 0 0 –
SBP — systolic blood pressure
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Certain aspects concerning drug interactions may be 
similar to those observed for ACEI or ARB. Currently, in the 
absence of direct observations of sacubitril/valsartan, this 
information should certainly be taken into account. The is-
sue of lithium use may be an example. Reversible increase of 
lithium concentration and its toxicity was documented during 
its simultaneous use with ACEI or ARB. Such a combination 
therapy is not recommended; similarly, such concomitant 
treatment with sacubitril/valsartan is also not recommended. 
Should such a treatment be necessary, careful monitoring of 
serum lithium levels is required.
Active metabolites of sacubitril (LBQ657) and valsartan are 
substrates of the OATP1B1, OATP1B3, OAT1, and OAT3 trans-
porters; valsartan is also a substrate for MRP2. Concomitant 
administration of inhibitors of OATP1B1, OATP1B3, OAT3 (e.g. 
rifampicin, cyclosporine), and OAT1 (e.g. tenofovir, cidofovir) or 
MRP2 (e.g. ritonavir) affect their pharmacokinetics and increase 
their bioavailability (area under curve [AUC]).
The use of sacubitril/valsartan impacts other drugs that 
are substrates for OATP1B1 and OATP1B3, e.g. statins. If used 
with sacubitril/valsartan, a 1.4–2-fold higher concentration 
of atorvastatin and its metabolites was observed; therefore, 
a dose reduction may be necessary when using both drugs.
To a limited extent, sacubitril/valsartan is metabolised 
by CYP450 enzymes, hence it is unlikely to interact with 
these enzymes.
Other drug interactions
Concomitant use of sacubitril/valsartan and metformin re-
duces the bioavailability of metformin (decrease in Cmax and 
AUC by 23%).
Drugs leading to blood pressure drop, e.g. nitroglycerin, 
phosphodiesterase-5 (PDE-5) inhibitors, may potentiate the 
hypotensive effect of sacubitril/valsartan.
TRANSFER OF SACUBITRIL/VALSARTAN  
RESEARCH BENEFITS TO CLINICAL PRACTICE
Heart failure is an important and difficult issue. In light of 
the PARADIGM-HF study results and analyses, the new drug 
sacubitril/valsartan is a promising medication, bringing the first 
possibility, in many years, of significant improvement of the 
prognosis of patients with symptomatic HF, who are already 
on optimal therapy. However, implementation of ARNI in 
clinical practice may be challenging for physicians. This ap-
plies mainly to the possibility of finding appropriate patients 
in the real world, keeping in mind the PARADIGM-HF criteria. 
Another issue may be a too cautious approach to modifica-
tion of existing treatment by clinicians and patients in subjects 
with stable course of HF. Therefore, it is worth recalling the 
PARADIGM-HF data showing that even patients with HF and 
NYHA class II (70%), who were treated with enalapril in the 
control arm, had significant risk of events. In 15% of these 
patients the primary endpoint was recorded, and 8% died of 
cardiovascular causes within 12 months. It also seems that 
based on the data showing significant reductions in 30-day 
hospitalisations and early reduction of sudden death, clinicians 
should wait until HF becomes worse.
Practical guidance on how to use sacubitril/valsartan
Starting and optimisation of treatment with sacubitril/valsartan 
during outpatient care should include the following steps:
•	 Candidates for sacubitril/valsartan therapy:
 — symptomatic HF NYHA class II or III treated on an out-
patient basis;
 — optimal medical treatment as per the guidelines;
 — hospitalised for HF within last 12 months;
 — clinical stability for at least one month;
 — LVEF £ 35%;
 — SBP ≥ 95 mm Hg, no symptomatic hypotension related 
to ACEI or ARB;
 — NT-proBNP ≥ 400 pg/mL;
 — creatinine clearance ≥ 30 mL/kg/1.73 m2.
•	 Before initiation of treatment:
 — check blood potassium level and eGFR;
 — discontinue ACEI and ARB.
•	 Initiation of sacubitril/valsartan:
 — allow at least 36 h from the last ACEI dose. Do not com-
bine ACEI and sacubitril/valsartan!
 — administer sacubitril/valsartan 2 × 24/26 mg;
 — gradually increase the dose to 2 × 49/51 mg followed 
by 97/203 mg while monitoring SBP.
•	 Long-term treatment rules:
 — avoid ACEI, and PDE-5 inhibitors;
 — continue BB, MRA, and ivabradine;
 — unless haemodynamically unstable, do not discontinue 
sacubitril/valsartan for exacerbation of HF;
 — use NT-proBNP instead of BNP for assessment of clini-
cal status;
 — monitor blood potassium and creatinine levels.
CONCLUSIONS
Considering the significant risk of events, individuals with 
HFrEF and NYHA class II or III treated with ACEI/ARB and 
chronic stable status of the disease should be considered as 
candidates for conversion to sacubitril/valsartan. Starting with 
a low dose and gradual up-titration to ensure good toler-
ance may be relevant in patients treated with low doses of 
ACEI/ARB or presenting with low SBP. There are no satisfactory 
data on the benefits and safety of initiating sacubitril/valsartan 
therapy in patients with worsening HF or de novo HF, or in 
patients not previously treated with ACEI/ARB. The results of 
a number of ongoing studies on ARNI are expected to increase 
our experience with this class of drugs.
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